Lenalidomide Grindeks

Lenalidomide, the active ingredient in Lenalidomide Grindeks, is an immunomodulatory imide drug presented as an oral tablet for oral use. It is indicated for the treatment of certain blood cancers, including multiple myeloma, myelodysplastic syndromes with del(5q), and mantle cell lymphoma, in adult patients who have relapsed or refractory disease.

GNH USA supplies Lenalidomide Grindeks as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide, ensuring quality assurance and regulatory compliance across all markets globally.

Lenalidomide is an immunomodulatory imide drug used in hematologic malignancies. - Multiple Myeloma: improves progression‑free survival and overall response in patients with relapsed or refractory disease. - Myelodysplastic Syndromes with del(5q): induces transfusion independence and cytogenetic remission in eligible patients. - Mantle Cell Lymphoma: contributes to disease control as part of combination therapy in relapsed or refractory cases.

Lenalidomide may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Fatigue: persistent tiredness reported by many patients. - Neutropenia: reduced neutrophil count increasing infection risk. - Thrombocytopenia: lowered platelet levels leading to bleeding tendencies. - Anemia: decreased red blood cell count causing weakness. - Diarrhea: loose stools that may affect hydration. - Rash: skin irritation or erythema.

Serious or Rare Side Effects: - Venous thromboembolism: deep vein thrombosis or pulmonary embolism. - Severe neutropenia: profound immune suppression requiring medical intervention. - Severe thrombocytopenia: significant bleeding risk. - Secondary primary malignancies: emergence of new cancers. - Hepatotoxicity: liver enzyme elevations or injury. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.

Before initiating therapy, clinicians should evaluate patient history and monitor for specific risks. - Pregnancy: contraindicated (Category X); avoid use in pregnant women. - Thromboembolic risk: assess history and consider prophylactic anticoagulation. - Hematologic monitoring: perform regular CBC to detect cytopenias. - Renal impairment: adjust dosing and monitor renal function. - Store at below 25°C: keep in the original pack, protect from moisture and light.

Lenalidomide can interact with several drug classes; careful review is essential.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin): may markedly reduce lenalidomide exposure. - Anticoagulants (e.g., warfarin): increased risk of bleeding. - Live vaccines: heightened risk of infection due to immunosuppression.

Moderate Interactions (Monitor Closely): - P‑glycoprotein inhibitors (e.g., verapamil): may increase plasma levels. - Immunosuppressants (e.g., cyclosporine): may augment toxicity. - Hormonal contraceptives: reduced effectiveness, requiring additional contraceptive measures.